ArticleAnalytical and bioanalytical chemistry2026
Development and validation of a multiplexed targeted HILIC-HRMS assay for quantitative analysis of hepatocellular carcinoma circulating biomarkers.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sub-3 μm porous graphitic carbon for highly polar metabolomics: orthogonal selectivity and comparison with HILIC and reversed-phase chromatography.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Early and accurate diagnosis of hepatocellular carcinoma (HCC) remains a major clinical challenge, particularly in patients with chronic hepatitis C virus (HCV) infection, where standard biomarkers such as alpha-fetoprotein (AFP) often lack sensitivity and specificity. Numerous biomarkers have emerged from untargeted metabolomics and lipidomics approaches; nevertheless, most of these studies provide only relative amounts and do not perform quantitative analysis as further validation. To address this challenge, we developed and validated a targeted method to quantitatively measure panels of biomarkers previously identified as predictive of HCC in untargeted analyses. A high-throughput (6 min) HILIC-HRMS method, based on a multiplexing-HRMS strategy, was developed and validated to measure a panel of lysophosphatidylcholines (LPCs) and carnitines (CARs) in plasma samples from 92 HCC patients. The method showed satisfactory performances in terms of sensitivity (LOD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.